SCHEMBL10240588

SCHEMBL10240588

Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)CN(C)CC3)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 10/20 0.51
DRD3 P35462 10/20 0.51
MAPT P10636 1/20 0.49
HTR6 P50406 10/20 0.47
HTR2C P28335 9/20 0.47
HTR2A P28223 8/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2C9 P11712 3/20 0.47
CYP2C19 P33261 3/20 0.47
CYP2D6 P10635 2/20 0.47
BRD4 O60885 1/20 0.45
LMNA P02545 3/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
RECQL P46063 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9959653 0.99 DRD2 (0.50) DRD2DRD3MAPTHTR6HTR2C
SCHEMBL13757713 0.98 DRD2 (0.50) DRD2DRD3MAPTHTR6HTR2C
Hydrochloric Acid SCHEMBL3147505 0.97 DRD2 (0.49) DRD2DRD3MAPTHTR6HTR2C
SCHEMBL13757730 0.83 HTR6 (0.57) DRD2DRD3HTR6HTR2CHTR2A
SCHEMBL5242130 0.83 MAPT (0.51) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL3155920 0.82 HTR6 (0.56) DRD2DRD3HTR6HTR2CHTR2A
SCHEMBL3353563 0.81 WDR5 (0.51) DRD2DRD3HTR6HTR2CHTR2A
SCHEMBL10239980 0.80 HTR6 (0.53) DRD2DRD3MAPTHTR6HTR2C
SCHEMBL3142771 0.79 ESR2 (0.53) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL10238667 0.79 NPSR1 (0.47) DRD2DRD3MAPTHTR6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007729-B1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS ESTEVE LABOR DR (ES) 2012-06-27 EP disclosed
US-20090209528-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2009-08-20 US disclosed
US-20090209528-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209528-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS HTR6, HTR5A, HTR7 DRD2 110/4885DRD3 341/4885MAPT 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.